HIV integrase inhibitors

US7893055B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Michael A. Walker · Durham, US
• Chen Li · South Glastonbury, US
• Katharine A. Grant-Young · Madison, US
• John D. Matiskella · Wallingford, US
• B. Narasimhulu Naidu · Durham, US
• Jacques Banville · St-Hubert, CA
• Francis Beaulieu · Elliot Lake, CA
• Carl Ouellet · Boucherville, CA
• Annapurna Pendri · South Glastonbury, US
• Roger Remillard · Napierville, CA
• Yasutsugu Ueda · Clinton, US
• Ting T. Yin · Hamden, US

Key dates

• Filing date: Jun 26, 2007
• Grant date: Feb 22, 2011
• Expiry date: Nov 26, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.